SCHEMBL1144985

SCHEMBL1144985

COc1ccc(F)c2[nH]c(C(=O)O)cc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.77
HPGD P15428 2/20 0.77
IDO1 P14902 9/20 0.65
TDO2 P48775 9/20 0.65
LMNA P02545 2/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 2/20 0.47
EIF4A3 P38919 2/20 0.46
HRH4 Q9H3N8 1/20 0.45
FBP1 P09467 1/20 0.45
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25812174 0.88 KDM4E (0.59) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL3602542 0.87 KDM4E (1.00) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL29824959 0.87 KDM4E (1.00) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL20505200 0.87 KDM4E (0.57) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL30310687 0.87 KDM4E (0.57) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL22747188 0.84 IDO1 (0.75) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL29974758 0.84 IDO1 (0.75) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL1144735 0.83 KDM4E (0.79) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL24019767 0.82 KDM4E (0.52) KDM4EHPGDIDO1TDO2LMNA
SCHEMBL1144707 0.82 KDM4E (0.52) KDM4EHPGDIDO1TDO2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 US disclosed
US-12545671-B2 Compound having biological activity such as antiviral activity NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE (JP) 2026-02-10 US disclosed
US-20250101038-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-03-27 US disclosed
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2024-11-19 US disclosed
CN-118715204-A Compounds of formula (I) 普赛洛私人有限公司 2024-09-27 CN disclosed
EP-3928836-B1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-09-18 EP disclosed
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-08-15 US disclosed
US-20240246951-A1 COMPOUND HAVING BIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE (JP) 2024-07-25 US disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 US disclosed
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 US disclosed
EP-3377483-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2018-09-26 EP disclosed
EP-2297163-B1 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER (US) 2015-07-08 EP disclosed
US-8318762-B2 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-11-27 US disclosed
US-8318762-B2 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-11-27 US disclosed
EP-2297163-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2011-03-23 EP disclosed
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER, INC. (US) 2011-02-03 US disclosed
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER, INC. (US) 2011-02-03 US disclosed
WO-2009144554-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS PFIZER, INC. (US) 2009-12-03 WO disclosed
WO-2009144554-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS PFIZER, INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101038-A1 COMPOUNDS NLN, SLC18A2, PYGB KDM4E 3243/4885HPGD 694/4885IDO1 3088/4885
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 KDM4E 2755/4885HPGD 178/4885IDO1 51/4885
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 KDM4E 3205/4885HPGD 4005/4885IDO1 3030/4885
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL KDM4E 2746/4885HPGD 3164/4885IDO1 1609/4885
US-12545671-B2 Compound having biological activity such as antiviral activity SARS1, ACE2, ACE KDM4E 4419/4885HPGD 3025/4885IDO1 1902/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 KDM4E 2755/4885HPGD 178/4885IDO1 51/4885
US-20240246951-A1 COMPOUND HAVING BIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY RNASE1, ZC3HAV1, ACE KDM4E 3692/4885HPGD 3028/4885IDO1 872/4885
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL KDM4E 2930/4885HPGD 1608/4885IDO1 1633/4885
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB KDM4E 1055/4885HPGD 567/4885IDO1 3608/4885
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL KDM4E 2930/4885HPGD 1608/4885IDO1 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.